MYL2 and ovarian carcinoma: Our results also revealed that SIK2 directly phosphorylates MYLK at Ser343, suggesting that SIK2 enhances cell motility and metastasis by directly phosphorylating MYLK and activating MYLK/MYL2 signalling in ovarian cancer.